aires

We are a specialty pharmaceutical company
focused on commercializing best-in-class
products for the United States market.

We are a specialty pharmaceutical company focused on commercializing best-in-class gastroenterology products for the United States market.
Find out more

FDA accepts New Drug Application for Aemcolo (Rifamycin SV MMX®) and sets PDUFA Date for November 16, 2018

Home > News Upon FDA Approval, Aries Pharmaceuticals, Inc. to Lead U.S. Commercial...

FDA accepts New Drug Application for Methylene Blue MMX™ and sets PDUFA Date for May 21, 2018

MB MMX™ is a first-in-class drug candidate based on Cosmo Pharmaceuticals’ proprietary MMX delivery
technology.

Aries Pharmaceuticals and Olympus Initiate Co-Promotion of Eleview™ at the American College of Gastroenterology’s World Congress

Aries Pharmaceuticals, Inc. enters co-promotion agreement in the U.S. with Olympus for Eleview™.

Aries Pharmaceuticals, Inc. Launches Eleview™ for use in Gastrointestinal Endoscopic Procedures

Novel Development in Submucosal Injection Agents Elevates Lesions to Facilitate Removal

Remimazolam

An ultra-short-acting intravenous benzodiazepine sedative/anesthetic.

Aemcolo (Rifamycin SV MMX®)

A non-absorbable antibiotic for the treatment of bacterial infections of the colon.

Methylene Blue MMX™ (MB MMX)

novel application of methylene blue to stain the mucosa to discover pre-cancerous lesions and polyps

Eleview®

injectable composition for use in edoscopic removal of adenomas or polyps

Visit Our Careers Page for Current Job Listings

If you want to be part of building something special – come join...